Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Autoimmune
Cancer
Cardiovascular
COVID-19
Health Topics
Infectious
Sepsis: Page 2
T2 Biosystems submits FDA 510(k) premarket notification for biothreat panel
By
LabPulse.com staff writers
The panel is a fully-automated, direct-from-blood test designed to run on the T2 Biosystem’s FDA-cleared T2Dx Instrument and simultaneously detects six pathogens identified as threats by the CDC.
May 23, 2023
Immunexpress to present data on host-response sepsis test at ECCMID 2023
By
LabPulse.com staff writers
The firm's SeptiCyte Rapid molecular test for sepsis uses reverse transcription polymerase chain reaction to quantify the relative expression levels of host-response genes isolated from whole blood.
April 5, 2023
Ad Astra Diagnostics files FDA 510(k) application for point-of-care hematology analyzer
By
LabPulse.com staff writers
The QScout hematology platform is a rapid testing system that would operate at the point of care to provide measurements indicative of disease and infection, including sepsis.
March 30, 2023
Sepsis increases heart failure, rehospitalization risks following hospital discharge
By
Elissa Wolfson
Hospital patients who initially had or developed sepsis were at higher risk for heart failure, rehospitalization, or death within 12 years than patients without sepsis.
February 1, 2023
Vision Research supplies high-speed camera for Cytovale point-of-care sepsis test
By
LabPulse.com staff writers
An enabling technology for flow cytometry, the Vision Research Phantom VEO 710 high-speed camera resolves blood cells as they move through a microfluidics channel at three meters per second.
January 30, 2023
Asep Medical inks joint venture term sheet with Sansure Biotech, preps sepsis test for launch in China
By
LabPulse.com staff writers
As part of the agreement, Sansure will invest in the joint venture. Asep Medical will provide a sublicense to patent rights to its Sepset sepsis test for the Chinese marketplace and would receive a royalty when the test is marketed.
January 30, 2023
T2 Biosystems nabs contract extension with group purchasing organization
By
LabPulse.com staff writers
Products covered under the contract with Vizient, a purchasing organization for healthcare institutions, include the T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel. All detect sepsis-causing bacterial and fungal pathogens from whole blood.
December 28, 2022
DeepUll obtains 20-million-euro loan to develop point-of-care sepsis test
By
LabPulse.com staff writers
DeepUll’s sepsis testing product is being developed to detect more than 250 different pathogens and approximately 15 resistance genes in one hour from 10 mL of whole blood.
December 13, 2022
Blu Biotech collaborates with University of Michigan on breath biomarkers for sepsis and ARDS detection
By
LabPulse.com staff writers
ARDS and sepsis are life-threatening and can be difficult to detect early. Blu Biotech, University of Michigan, and the Weil Institute seek to change that with the development of biomarkers for both conditions.
November 16, 2022
At AMP 2022, Immunexpress launches rapid test for sepsis requiring two minutes hands-on time
By
Leo O'Connor
The firm obtained FDA 510(k) clearance for its SeptiCyte Rapid test last year. The test runs on the sample-to-answer Biocartis Idylla molecular testing platform.
November 5, 2022
Biocartis to present 9 abstracts on MDx platform, assays at AMP 2022
By
LabPulse.com staff writers
One study evaluates the performance of the Immunexpress SeptiCyte Rapid ethylenediamine tetraacetic acid blood-compatible cartridges on the Idylla platform.
October 31, 2022
Avails Medical nabs $1.7M to develop AST test
By
LabPulse.com staff writers
The money will be used to further develop the fully electrical Avails Medical eAST system, which provides a time-to-results average of five hours. The system will enable healthcare providers to determine the most effective antibiotic treatment for patients with severe bloodstream infections, such as sepsis, particularly those involving multidrug-resistant pathogens.
August 31, 2022
Previous Page
Page 2 of 6
Next Page
